153 related articles for article (PubMed ID: 19006482)
1. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
Pecherstorfer M
Expert Opin Pharmacother; 2008 Dec; 9(17):3111-9. PubMed ID: 19006482
[TBL] [Abstract][Full Text] [Related]
2. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
McCormack PL; Plosker GL
Drugs; 2006; 66(5):711-28. PubMed ID: 16620148
[TBL] [Abstract][Full Text] [Related]
3. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
Body JJ; Diel IJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
Ann Oncol; 2003 Sep; 14(9):1399-405. PubMed ID: 12954579
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Bauss F; Bergström B
Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
Pecherstorfer M
Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
[TBL] [Abstract][Full Text] [Related]
7. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
8. Ibandronate in metastatic bone pain.
Heidenreich A; Ohlmann C; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
[TBL] [Abstract][Full Text] [Related]
9. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
10. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
[TBL] [Abstract][Full Text] [Related]
11. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
13. [ESMO Conference 2004. Ibandronate in the treatment of bone metastasis].
Longo F; Mansueto G
Tumori; 2004; 90(6):30-5. PubMed ID: 15762375
[No Abstract] [Full Text] [Related]
14. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
[TBL] [Abstract][Full Text] [Related]
15. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
16. Ibandronate in metastatic bone disease: a review of preclinical data.
Bauss F; Body JJ
Anticancer Drugs; 2005 Feb; 16(2):107-18. PubMed ID: 15655407
[TBL] [Abstract][Full Text] [Related]
17. Ibandronate reduces skeletal morbidity in patients with breast cancer.
Tripathy A D; Diel I; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
19. Managing metastatic bone disease: three case studies.
Coleman R; Heidenreich A; Bell R
Semin Oncol; 2004 Oct; 31(5 Suppl 10):83-6. PubMed ID: 15490382
[TBL] [Abstract][Full Text] [Related]
20. Review of ibandronate in the treatment of osteoporosis.
Chapurlat RD; Delmas PD
Expert Opin Pharmacother; 2003 Mar; 4(3):391-6. PubMed ID: 12614191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]